title: In hemodialysis, adiponectin, and pro-brain natriuretic peptide levels may be subjected to variations in body mass index.
abstract: Adiponectin exerts cardiovascular protective actions, although some studies have shown the opposite. In hemodialysis, obese subjects display lower mortality rates despite hypoadiponectinemia, while higher adiponectin concentrations correlate with an elevated cardiovascular risk in nonobese subjects. The aim of the study is to suggest that adiponectin level variations are associated with differences in the body mass index (BMI). The interplay between adiponectin and pro-brain natriuretic peptide (Pro-BNP) levels may vary according to body fat mass. Fifty-two chronic hemodialysis patients were divided into three groups. Group A, BMI<25 (n=20); Group B, BMI 25 to 30 (n=21), and Group C, BMI>30 (n=11). Diabetics: Group A 10%; Group B 6 29%; Group C 55%, P=0.027. Determinations: Adiponectin, Pro-BNP, insulin, insulin resistance (HOMA), troponin T, nutritional status, ultrafiltration rates, C-reactive protein (CRP), vascular accesses, and echocardiography. Group A: adiponectinemia positively and significantly correlated with Pro-BNP, CRP, and troponin T. As BMI increased, adiponectin, Pro-BNP, and malnutrition significantly decreased, while insulin, HOMA, and ultrafiltration rates significantly increased. Cardiac restriction was significantly higher in obese patients. In all groups, Pro-BNP and troponin T displayed a strong positive correlation. In low-BMI subjects, high Pro-BNP and adiponectin, low myocardial restriction, and worse nutritional status were prevalent. In obesity, hypoadiponectinemia stimulates cardiac remodeling, cardiac hypertrophy, and decreased stretching, rendering Pro-BNP levels low despite high ultrafiltration rates. Thus, adiponectin correlates inversely with BMI, probably playing different cardiovascular roles as BMI changes.
authors.affiliation: Department of Nephrology, Hospital Británico de Buenos Aires, Buenos Aires, Argentina. htrimarchi@hotmail.com
authors.forename: Hernan
authors.initials: H
authors.lastname: Trimarchi
authors.forename: Alexis
authors.initials: A
authors.lastname: Muryan
authors.forename: Mariana
authors.initials: M
authors.lastname: Dicugno
authors.forename: Mariano
authors.initials: M
authors.lastname: Forrester
authors.forename: Fernando
authors.initials: F
authors.lastname: Lombi
authors.forename: Pablo
authors.initials: P
authors.lastname: Young
authors.forename: Vanesa
authors.initials: V
authors.lastname: Pomeranz
authors.forename: Romina
authors.initials: R
authors.lastname: Iriarte
authors.forename: Nanci
authors.initials: N
authors.lastname: Barucca
authors.forename: Vicente
authors.initials: V
authors.lastname: Campolo-Girard
authors.forename: Mirta
authors.initials: M
authors.lastname: Alonso
authors.forename: Bengt
authors.initials: B
authors.lastname: Lindholm
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D006332:Cardiomegaly / Q000097:blood / Q000209:etiology; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D009765:Obesity / Q000097:blood / Q000628:therapy; D011446:Prospective Studies; D006435:Renal Dialysis
chemical_list: D052242:Adiponectin; D020097:Natriuretic Peptide, Brain